Vanda Pharmaceuticals Inc.(VNDA)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$5.95
- 52-Week Range
- $4.14 – $9.94
- YTD
- -27.88%
- IV Rank (30D)
- 7.74
- Straddle Price
- $1.32
- P/C Vol Ratio
- 0.06
- Market Cap
- $0.4B
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.53% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.03% (VRP-adj) |
| WACC | 9.95% |
| Volatility Risk Premium | +95.7pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -1.7% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -85.3% |
| Book / Price | 77.9% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 93.3% |
| FCF Margin (TTM) | -58.5% |
| Debt / Equity | 0.01 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $6.68 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $6.21 |
| Bollinger Width / SMA20 | 181.8% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: ABT, PFE, REGN, TEVA
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$11.21
Current Price
$5.87
Deviation
+50.0%
Forward-Return Rank
LONG
gates ✓
?
| Horizon | Expected α | z Pred | Blended z | Rank % | Active? |
|---|---|---|---|---|---|
| 21d | -9.4% ⚠ | -2.01 | +0.71 | 66.3% | — |
| 42d | -12.0% ⚠ | -1.78 | +0.82 | 67.3% | — |
| 63d | -12.8% ⚠ | -1.48 | +0.98 | 73.6% | — |
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon).
For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference.
⚠ flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 22.1× · 4 peers |
| Peer EV/EBITDA | n/a | 0% | median 12.8× · 4 peers |
| Peer P/B | $11.85 | 50% | median 2.5× · 4 peers |
| Peer P/S | $10.57 | 50% | median 2.9× · 4 peers |
| Market Anchor (SMA50) | $6.68 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.4B
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company…
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -6.88% | 6 |
| Feb | +6.20% | 6 |
| Mar | -5.38% | 6 |
| Apr | -1.60% | 6 |
| May | -1.70% | 6 |
| Jun | +8.68% | 6 |
| Jul | -3.42% | 5 |
| Aug | -2.62% | 5 |
| Sep | -2.59% | 5 |
| Oct | -0.68% | 5 |
| Nov | +2.95% | 5 |
| Dec | +1.86% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $6.18
SMA 50: $6.65
SMA 200: $6.37
Current: $5.87
EMA 12: $6.12
EMA 26: $6.31
MACD: -0.1889 | Signal: -0.0003
BEARISH
ADX (14): 9.64
RANGE
+DI: 18.16
−DI: 21.27
Momentum Oscillators
RSI (14): 38.45
NEUTRAL
Stoch %K: 13.77
Stoch %D: 16.07
Williams %R: -98.28
Volume & Volatility
BB Upper: $6.55
BB Lower: $5.81
NEUTRAL
OBV: 47,534,149
Vol SMA 20: 952,813
Vol ROC: 63.11%
ATR: $0.28
True Range: $0.29
HV 20: 39.6%
HV 30: 60.2%
HV 60: 63.9%
Data Summary
Data Points: 500
Last Updated: 2026-06-13T13:41:59.241000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Earnings History
6 of 8 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-07-31 | After-Close | 11.03% | 7.19% | 0.65x | Within |
| 2024-11-06 | After-Close | 24.18% | 5.97% | 0.25x | Within |
| 2025-02-13 | After-Close | 10.22% | 3.87% | 0.38x | Within |
| 2025-05-07 | After-Close | 12.01% | 3.64% | 0.30x | Within |
| 2025-07-31 | After-Close | 61.62% | 1.64% | 0.03x | Within |
| 2025-10-29 | After-Close | 14.98% | 18.91% | 1.26x | Exceeded |
| 2026-02-11 | After-Close | 12.87% | 18.02% | 1.40x | Exceeded |
| 2026-05-06 | After-Close | 15.60% | 11.37% | 0.73x | Within |
Options Activity
- IV Rank (30D)
- 7.74
- IV Rank (7D)
- 100
- Avg IV
- 129.9%
- Straddle (30D)
- $1.32
- Straddle (7D)
- $0.62
- P/C Volume
- 0.06
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.06
- Correlation (SPY)
- 16.0%
- R²
- 0.03
- Ann. Volatility
- 81.7%
- SPY Volatility
- 12.3%
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 59,118,901 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$5.80M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | GROUP ONE TRADING LLC Custodian | $2.02M | 34.86% | 2026-03-31 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $1.72M | 29.72% | 2026-03-31 |
| 3 | CITADEL ADVISORS LLC Custodian | $907.97K | 15.67% | 2026-03-31 |
| 4 | SIMPLEX TRADING, LLC Custodian | $886.55K | 15.30% | 2026-03-31 |
| 5 | JANE STREET GROUP, LLC Custodian | $258.43K | 4.46% | 2026-03-31 |
4 filers$1.06M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC Custodian | $418.06K | 39.57% | 2026-03-31 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $395.94K | 37.48% | 2026-03-31 |
| 3 | SIMPLEX TRADING, LLC Custodian | $157.55K | 14.91% | 2026-03-31 |
| 4 | GROUP ONE TRADING LLC Custodian | $84.99K | 8.04% | 2026-03-31 |
Insider Activity
Latest: 2026-06-08
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | RICHARD W DUGAN | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-06-08 | Tage Honore | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-06-08 | Charles Cliff Duncan | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-06-08 | Anne Sempowski Ward | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-06-08 | Phaedra Chrousos | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-06-08 | Daniel Patrick McGuire | SVP, GC and Secretary | Award (A) | +80,000 | — | EDGAR | |
| 2026-06-08 | Stephen Ray Mitchell | Director | Award (A) | +41,600 | — | EDGAR | |
| 2026-05-20 | Stephen Ray Mitchell | Director | Gift (G) | −25,836 | — | EDGAR | |
| 2026-04-24 | Charles Cliff Duncan | Director | Award (A) | +57,101 | — | EDGAR | |
| 2026-03-04 | Mihael Hristos Polymeropoulos | President and CEO | Sell (S) | −156,235 | $8.17 | -$1.28M | EDGAR |
| 2026-03-04 | Timothy Williams | SVP & General Counsel | Sell (S) | −42,434 | $8.27 | -$350.8K | EDGAR |
| 2026-03-04 | Gunther Birznieks | SVP, Business Development | Sell (S) | −42,431 | $8.27 | -$350.7K | EDGAR |
| 2026-03-04 | Joakim Wijkstrom | SVP, Chief Marketing Officer | Sell (S) | −30,800 | $8.27 | -$254.6K | EDGAR |
| 2026-03-04 | Kevin Patrick Moran | SVP, CFO & Treasurer | Sell (S) | −42,442 | $8.27 | -$350.8K | EDGAR |
| 2026-02-24 | Tage Honore | Director | Sell (S) | −30,000 | $8.03 | -$240.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
33 insiders · @ $5.87
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | 3,065,852 | $18.00M | -$20.62M | 4 | 2009-10-15 |
| 2 | KEVIN TANG | 10%+ Owner | 2,884,671 | $16.93M | -$3.12M | 3 | 2010-01-13 |
| 3 | TANG CAPITAL PARTNERS LP | 10%+ Owner | 2,715,852 | $15.94M | -$3.42M | 7 | 2010-01-19 |
| 4 | Mihael Hristos Polymeropoulos | President and CEO | 2,704,496 | $15.88M | -$27.73M | 76 | 2026-03-04 |
| 5 | DEERFIELD MANAGEMENT COMPANY, L.P. | 10%+ Owner | 2,660,207 | $15.62M | $42.54M | 4 | 2016-09-19 |
| 6 | Deerfield Mgmt L.P. | 10%+ Owner | 2,152,952 | $12.64M | $600.9K | 1 | 2015-12-18 |
| 7 | DEERFIELD PARTNERS, L.P. | 10%+ Owner | 850,778 | $4.99M | -$111.36M | 1 | 2016-09-26 |
| 8 | Gunther Birznieks | SVP, Business Development | 494,197 | $2.90M | -$2.02M | 20 | 2026-03-04 |
| 9 | Kevin Patrick Moran | SVP, CFO & Treasurer | 412,015 | $2.42M | -$1.05M | 19 | 2026-03-04 |
| 10 | Timothy Williams | SVP & General Counsel | 377,450 | $2.22M | -$1.55M | 22 | 2026-03-04 |
| 11 | Joakim Wijkstrom | SVP, Chief Marketing Officer | 333,469 | $1.96M | -$706.5K | 17 | 2026-03-04 |
| 12 | RICHARD W DUGAN | Director | 219,054 | $1.29M | -$556.6K | 25 | 2026-06-08 |
| 13 | James Patrick Kelly | EVP & Chief Financial Officer | 186,869 | $1.10M | -$1.41M | 24 | 2020-03-04 |
| 14 | William D Clark | Sr. VP, Chief Business Officer | 168,279 | $987.8K | -$2.80M | 17 | 2010-02-23 |
| 15 | Gian Piero Reverberi | SVP & Chief Commercial Officer | 165,384 | $970.8K | -$81.0K | 11 | 2020-03-04 |
| 16 | Phaedra Chrousos | Director | 164,950 | $968.3K | -$40.1K | 10 | 2026-06-08 |
| 17 | Anne Sempowski Ward | Director | 160,667 | $943.1K | $0 | 8 | 2026-06-08 |
| 18 | Tage Honore | Director | 135,069 | $792.9K | -$240.9K | 6 | 2026-06-08 |
| 19 | Richard L. Gulino | SVP, General Counsel & Sec. | 118,733 | $697.0K | -$395.1K | 6 | 2018-03-02 |
| 20 | Stephen Ray Mitchell | Director | 112,846 | $662.4K | -$540.0K | 15 | 2026-06-08 |
| 21 | Daniel Patrick McGuire | SVP, GC and Secretary | 109,982 | $645.6K | $0 | 1 | 2026-06-08 |
| 22 | Aranthan II Jones | Chief Corp. Affairs Officer | 98,804 | $580.0K | -$1.43M | 8 | 2021-09-17 |
| 23 | Charles Cliff Duncan | Director | 98,701 | $579.4K | $0 | 2 | 2026-06-08 |
| 24 | Thomas Watkins | Director | 69,505 | $408.0K | -$901.1K | 19 | 2022-06-03 |
| 25 | Paolo Baroldi | SVP & Chief Medical Officer | 53,165 | $312.1K | $47.6K | 11 | 2017-01-05 |
| 26 | Robert Repella | SVP & Chief Commercial Officer | 21,490 | $126.1K | -$1.29M | 5 | 2013-11-21 |
| 27 | John Joseph Feeney | SVP & Chief Medical Officer | 16,702 | $98.0K | -$674.6K | 14 | 2012-07-20 |
| 28 | MICHAEL F COLA | Director | 15,000 | $88.0K | $0 | 7 | 2019-06-17 |
| 29 | VINCENT MILANO | Director | 10,000 | $58.7K | $0 | 9 | 2018-06-15 |
| 30 | Brian K Halak | Director | 7,276 | $42.7K | $0 | 4 | 2010-03-30 |
| 31 | KENNETH BATE | Director | 5,000 | $29.4K | $0 | 3 | 2017-06-19 |
| 32 | Albert W. Gianchetti | Sr.VP,Chief Commercial Officer | 3,000 | $17.6K | $0 | 2 | 2008-01-08 |
| 33 | Stephanie Rast Irish | Acting CFO/Treasurer | 2,249 | $13.2K | -$408.1K | 7 | 2010-02-23 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 1.3 |
| P/S Ratio | 1.7 |
| EV/EBITDA | -2.1 |
| TTM Revenue | $0.2B |
| TTM Net Income | $-0.2B |
| TTM EPS | $-4.05 |
| ROE | -85.3% |
| Debt/Equity | 0.01 |